Compare Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF vs Philip Morris International Inc. — how do they compare? Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.66 (market cap $7.77B), while Philip Morris International Inc. trades at $201.19 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 40.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days and Philip Morris International Inc. for 85 Days on average.
| PDBC | PM | |
|---|---|---|
Market Cap | $7.77B | $312.50B |
Volume | 6,100,303 | 5,517,172 |
52-Week High | $20.10 | $200.50 |
52-Week Low | $13.16 | $144.33 |
Typical Hold Time | 56 Days | 85 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | $355.62B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PDBC (Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF) trades at $19.66, up 1.29% with strong bullish technical signals from moving averages. The ETF has delivered impressive performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by multiple institutional purchases.
The commodity ETF outlook remains positive given ongoing geopolitical risks and defensive sector rotation, though elevated short interest and overbought RSI readings suggest near-term consolidation risk. Commodity super-squeeze warnings from HSBC highlight potential upside while defensive ETF inflows support continued institutional demand.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
